TOP TEN perturbations for 1552335_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1552335_at
Selected probe(set): 1552335_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1552335_at (1552335_at) across 6672 perturbations tested by GENEVESTIGATOR:

glioma study 16 (LN-18) / normal astrocyte sample

Relative Expression (log2-ratio):3.4137468
Number of Samples:2 / 3
Experimental glioma study 16 (LN-18)
Human glioma cell line LN018 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37C and 5% CO2.
Control normal astrocyte sample
Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations.

male infertility study 1 (mJS5) / normal testicular lobules tissue (mJS10)

Relative Expression (log2-ratio):-2.54465
Number of Samples:8 / 8
Experimental male infertility study 1 (mJS5)
Human testicular lobules biopsy samples isolated from adult infertile patients whose seminiferous tubules contained spermatocytes but no spermatids. Tissue samples were classified based on modified Johnsen score (mJS) as mJS5.
Control normal testicular lobules tissue (mJS10)
Biopsies of human testicular lobules isolated from fertile vasectomized adult men with normal spermatogenesis. Histological analysis classified samples as mJS10 (modified Johnsen score 10).

male infertility study 1 (juvenile; Ad-) / normal testicular lobules tissue (mJS10)

Relative Expression (log2-ratio):-2.5153494
Number of Samples:2 / 8
Experimental male infertility study 1 (juvenile; Ad-)
Human testicular lobules biopsy samples isolated from prepubescent patients with undescended testes. Testes of these children contained very low level of A-dark (Ad-) spermatogonial cells.
Control normal testicular lobules tissue (mJS10)
Biopsies of human testicular lobules isolated from fertile vasectomized adult men with normal spermatogenesis. Histological analysis classified samples as mJS10 (modified Johnsen score 10).

male infertility study 1 (mJS2) / normal testicular lobules tissue (mJS10)

Relative Expression (log2-ratio):-2.482543
Number of Samples:7 / 8
Experimental male infertility study 1 (mJS2)
Human testicular lobules biopsy samples isolated from adult infertile patients whose seminiferous tubules contained almost exclusively Sertoli cells. Tissue samples were classified based on modified Johnsen score (mJS) as mJS2.
Control normal testicular lobules tissue (mJS10)
Biopsies of human testicular lobules isolated from fertile vasectomized adult men with normal spermatogenesis. Histological analysis classified samples as mJS10 (modified Johnsen score 10).

male infertility study 1 (mJS3) / normal testicular lobules tissue (mJS10)

Relative Expression (log2-ratio):-2.4564562
Number of Samples:3 / 8
Experimental male infertility study 1 (mJS3)
Human testicular lobules biopsy samples isolated from adult infertile patients whose seminiferous tubules contained Sertoli cells but rarely spermatogonia. Tissue samples were classified based on modified Johnsen score (mJS) as mJS3.
Control normal testicular lobules tissue (mJS10)
Biopsies of human testicular lobules isolated from fertile vasectomized adult men with normal spermatogenesis. Histological analysis classified samples as mJS10 (modified Johnsen score 10).

male infertility study 1 (juvenile; Ad+) / normal testicular lobules tissue (mJS10)

Relative Expression (log2-ratio):-2.3649979
Number of Samples:5 / 8
Experimental male infertility study 1 (juvenile; Ad+)
Human testicular lobules biopsy samples isolated from prepubescent patients with undescended testes. Testes of these children contained typical level of A-dark (Ad+) spermatogonial cells.
Control normal testicular lobules tissue (mJS10)
Biopsies of human testicular lobules isolated from fertile vasectomized adult men with normal spermatogenesis. Histological analysis classified samples as mJS10 (modified Johnsen score 10).

F. tularensis study 1 (tularensis Schu S4) / uninfected peripheral blood monocyte sample

Relative Expression (log2-ratio):-2.2223825
Number of Samples:4 / 6
Experimental F. tularensis study 1 (tularensis Schu S4)
Peripheral blood monocytes infected with the Schu S4 isolate of Francisella tularensis (100 MOI) for 24 hours.
Control uninfected peripheral blood monocyte sample
Peripheral blood monocytes uninfected.

glioma study 16 (LN-229) / normal astrocyte sample

Relative Expression (log2-ratio):1.9935713
Number of Samples:2 / 3
Experimental glioma study 16 (LN-229)
Human glioma cell line LN229 was cultured in DMEM supplemented with 10% FCS (fetal calf serum) and antibiotics at 37°C and 5% CO2.
Control normal astrocyte sample
Normal brain astrocytes. Clonetics normal human astrocytes (NHA) from Cambrex (primary-derived cultures) and cultured according to the manufacturer's recommendations.

BEZ235 study 1 (3.606 uM) / vehicle (DMSO) treated A2058 cell samples

Relative Expression (log2-ratio):1.9783621
Number of Samples:4 / 4
Experimental BEZ235 study 1 (3.606 uM)
A2058 cells treated with 3.606 uM NVP-BEZ235 for 24hours. The concentration corresponding to the IC90 of BKM120. Cells were maintained in DMEM, high glucose, 10% FCS, 1% pyruvate, 2% glutamine. BEZ235 is a mTOR/PI3K inhibitor; alternative names: [NVP-BEZ235] ATC code:---
Control vehicle (DMSO) treated A2058 cell samples
A2058 cells treated with vehicle (0.1% DMSO) for 24hours. Cells were maintained in DMEM, high glucose, 10% FCS, 1% pyruvate, 2% glutamine.

rheumatoid arthritis study 37 (mono; CD14+ CD16+) / rheumatoid arthritis study 37 (mono; CD14+ CD16-)

Relative Expression (log2-ratio):-1.9379082
Number of Samples:6 / 6
Experimental rheumatoid arthritis study 37 (mono; CD14+ CD16+)
Peripheral blood CD14+ CD16+ monocyte cell samples derived from patients with rheumatoid arthritis (RA). All patients were assigned to the treatment with disease-modifying antirheumatic drugs (DMARDs) i.e. tocilizumab (TCZ) and/or infliximab (IFX) and/or methotrexat (MTX). Patients characteristics: age 59.00±19.15 year; 3 males and 3 females; RF positive 4 (66.7%); ACPA positive 3 (50.0%); CRP 2.81±2.02 mg/dl; ESR 83.67±46.21 mm/hr; DAS28-CRP 5.06±1.22; DAS28-ESR 5.92±1.50; SDAI 28.76±19.03; CDAI 25.95±18.08; HAQ-DI 1.02±0.95; TJC28 8.17±6.4; SJC28 7.50±7.66; Pain, VAS 52.67±20.20; Physician GA, VAS 46.83 ±29.30 mm; Subject GA, VAS 56.00±17.61 mm
Control rheumatoid arthritis study 37 (mono; CD14+ CD16-)
Peripheral blood CD14+ CD16- monocyte cell samples derived from patients with rheumatoid arthritis (RA). All patients were assigned to the treatment with disease-modifying antirheumatic drugs (DMARDs) i.e. tocilizumab (TCZ) and/or infliximab (IFX) and/or methotrexat (MTX). Patients characteristics: age 59.00±19.15 year; 3 males and 3 females; RF positive 4 (66.7%); ACPA positive 3 (50.0%); CRP 2.81±2.02 mg/dl; ESR 83.67±46.21 mm/hr; DAS28-CRP 5.06±1.22; DAS28-ESR 5.92±1.50; SDAI 28.76±19.03; CDAI 25.95±18.08; HAQ-DI 1.02±0.95; TJC28 8.17±6.4; SJC28 7.50±7.66; Pain, VAS 52.67±20.20; Physician GA, VAS 46.83 ±29.30 mm; Subject GA, VAS 56.00±17.61 mm